Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib. — Masatoshi Kudo (2017) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.
Shared by
Masatoshi Kudo
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.
Editorial Material
2017
en
Authors
Masatoshi Kudo
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Editorial Material
2020
A new era of systemic therapy for intermediate and advanced stage hepatocellular carcinoma
Masatoshi Kudo
Editorial Material
2020
A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy
Masatoshi Kudo
Article
2025
Development and regulatory approval of a new systemic targeted therapy for advanced hepatocellular carcinoma.
Boris Pasche
,
Al B. Benson
,
Masatoshi Kudo
,
Anthony F. Shields
,
Hugo Jimenez
,
Alexandre Barbault
Article
2022
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
Masatoshi Kudo
Editorial Material
2016
Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma
Masatoshi Kudo
Discussion(0)
No comments yet. Be the first to comment.